Prospective study of intraocular bevacizumab for macular oedema in central retinal vein occlusion

Source: Ophthalmology
Area: News
A small 12 month prospective study has found that intraocular injections of bevacizumab (AvastinT) are helpful in treating macular oedema (MO) secondary to central retinal vein occlusion (CRVO), as long as they're given promptly.   The study randomised 60 eyes of 60 patients to intraocular injections of bevacizumab or sham injections every 6 weeks for 6 months. From month 6, all patients received intraocular injections of bevacizumab every 6 weeks for 6 months. The primary outcome measure was the proportion of patients gaining at least 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters at 12 months.   The following results were reported at 12 months:   . 18 of 30 patients (60.0%) in the bevacizumab/bevacizumab (bz/bz) group had gained at least 15 letters compared with 10 of 30 patients (33.3%) in the sham/bevacizumab (sh/bz) group (P < 0.05).   . The best corrected visual acuity (BCVA; a secondary endpoint)  ...